Schizophrenia and increased risks of cardiovascular disease.
about
Eating disorders in schizophrenia: implications for research and managementSmoke, Smoke, Smoke That CigaretteBifeprunox versus placebo for schizophreniaSchizophrenia: a multisystem disease?Cancer care for individuals with schizophreniaGuidelines for Reporting Articles on Psychiatry and Heart rate variability (GRAPH): recommendations to advance research communication.Dysfunction in the coagulation system and schizophreniaNutritional interventions for the adjunctive treatment of schizophrenia: a brief reviewCancer in patients with schizophrenia: What is the next step?Effects of the phencyclidine model of schizophrenia and nicotine on total and categorized ultrasonic vocalizations in ratsAnalysis of heart rate variability during auditory stimulation periods in patients with schizophrenia.Excess mortality in persons with severe mental disorders: a multilevel intervention framework and priorities for clinical practice, policy and research agendas.Meanings of participating in a lifestyle programme for persons with psychiatric disabilities.The evolution of drug development in schizophrenia: past issues and future opportunities.Testing the hypothesis of accelerated cerebral white matter aging in schizophrenia and major depressionMitochondrial respiration in peripheral blood mononuclear cells correlates with depressive subsymptoms and severity of major depression.Metabolic syndrome in antipsychotic naïve patients with schizophrenia: pooled analysis of data from three Indian studies.Resting-state high-frequency heart rate variability is related to respiratory frequency in individuals with severe mental illness but not healthy controls.A comparison of the nutrient intake of a community-dwelling first-episode psychosis cohort, aged 19-64 years, with data from the UK populationHow do General Practitioners experience providing care for their psychotic patients?Weight management in a cohort of Irish inpatients with serious mental illness (SMI) using a modular behavioural programme. A preliminary service evaluationRelative risk of diabetes, dyslipidaemia, hypertension and the metabolic syndrome in people with severe mental illnesses: systematic review and metaanalysis.Somatic diseases in patients with schizophrenia in general practice: their prevalence and health care.Impact of a nurse-led intervention to improve screening for cardiovascular risk factors in people with severe mental illnesses. Phase-two cluster randomised feasibility trial of community mental health teams.Pharmacotherapy for smoking cessation: pharmacological principles and clinical practice.Excess heart-disease-related mortality in a national study of patients with mental disorders: identifying modifiable risk factors.Endothelial nitric oxide synthetase genetic variants, metabolic syndrome and endothelial function in schizophrenia.General medical problems of incarcerated persons with severe and persistent mental illness: a population-based study.Metabolic Effects of Antidepressant TreatmentDevelopment and Reliability Testing of a Health Action Process Approach Inventory for Physical Activity Participation among Individuals with Schizophrenia.Quality of care for cardiometabolic disease: associations with mental disorder and rurality.Care provided by general practitioners to patients with psychotic disorders: a cohort studyMortality in schizophrenia: clinical and serological predictorsNeurodevelopmental and neurodegenerative models of schizophrenia: white matter at the center stage.Clinical characteristics of heavy and non-heavy smokers with schizophrenia.A well-being support program for patients with severe mental illness: a service evaluation.Accelerated white matter aging in schizophrenia: role of white matter blood perfusionMonitoring and prevalence rates of metabolic syndrome in military veterans with serious mental illness.Multimodal white matter imaging to investigate reduced fractional anisotropy and its age-related decline in schizophreniaThe comparison of glucose and lipid metabolism parameters in drug-naïve, antipsychotic-treated, and antipsychotic discontinuation patients with schizophrenia.
P2860
Q21284525-0945357F-34D0-4271-B2CA-C86AC7CEEF1EQ22242313-1FF275FB-4CAD-469F-95F3-54E76C3902F9Q24186774-E0BB6098-73CF-40D6-9543-80117DA10AFEQ24633845-1ABD22F4-1A5A-48E1-851A-54E82E000199Q27009111-80E5CAE4-1780-4D4E-9992-6E44293FDA93Q28067996-FE7EF46F-048A-4D48-9CBF-A4DC9D51BB81Q28068412-12376290-03A6-4CBB-A3CF-BFBC593011C9Q28248117-23B281F5-3CFE-4FE2-8116-B45561FFB85DQ30249107-F96DEA3A-A6EE-4B3F-92BF-2DF1FB36E412Q30354969-2DA9DDD0-8DDD-49A0-86B1-68DD9C99465AQ30362597-E05FF8C6-5FE1-4173-85F4-26EB4CBC6742Q30379171-5D63BAE7-B22A-4269-A1A3-38A567A0FD2BQ30395488-A2AEC485-2C4D-42B3-8318-9CFB08E9D4BFQ30487850-509BBBD1-6485-429C-AB99-90976BEB24AFQ30539567-B1A2B4D4-0EDD-483E-BCD5-D765C0C87FC9Q30582601-D889E178-3D8B-49A2-9920-4F1CAB915D99Q30736365-C19F43BE-26DB-4EE1-9EF4-D5D656543D0FQ30828935-5051F67C-E3A2-41A3-9178-D86E1EC9895EQ31010040-1C5D2DBA-D2D9-4D5A-B2B8-C7DB66BBB608Q33289227-DC1EC96B-6F61-43E2-9620-44AEC7025C53Q33369547-7D198EED-D89D-4975-B7EC-5AC7882C6720Q33371995-99C8BF2F-1D5C-4173-953C-4851CA6E3A00Q33442059-C23162FD-33D4-4BBF-96CA-241A660E1F0AQ33539405-E0378E82-EA44-4ADB-875E-B01AF5A46492Q33582051-65D7E03B-F7E6-4E9E-89E6-6586DE3DF2CBQ33663582-359A1910-736F-4872-879D-AB15340E6FA3Q33688651-DD01A55F-C96D-445A-BB17-84097A1A8500Q33693324-F7CF4B2E-A1CB-4AF6-B05C-61FE4EEDAD1BQ33712365-BCA1F7F0-4133-4578-BDA5-3EADFDA55495Q33732122-538CFCE8-19B7-4311-A4F1-EBC73F457C2BQ33755431-A5F558BF-3BA6-482A-903A-FAE5E5F77850Q33756112-DA4BE1A4-5786-4EA3-AB55-EBCAB2A961FBQ33762540-D826B1B9-906E-4B7C-81B7-8EA2ACD8A532Q33762573-8487D691-869C-4F3F-B030-7D87D8DEC401Q33775576-08F2826C-B007-4A34-95D2-B14BC87ABEAFQ33850375-86FFEEAB-05D5-4537-B4B9-D7E75AA48CFCQ33864602-3B1DB094-4718-4A22-91F7-88F1485A2597Q33889282-FC3A4A24-4B79-4B5D-916F-D11718899FD9Q33907356-8AC8F7E2-0885-4249-BCD4-8CE3C49CF218Q33968686-D72B9078-8599-4F48-AA38-F4F609B8AADB
P2860
Schizophrenia and increased risks of cardiovascular disease.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Schizophrenia and increased risks of cardiovascular disease.
@ast
Schizophrenia and increased risks of cardiovascular disease.
@en
type
label
Schizophrenia and increased risks of cardiovascular disease.
@ast
Schizophrenia and increased risks of cardiovascular disease.
@en
prefLabel
Schizophrenia and increased risks of cardiovascular disease.
@ast
Schizophrenia and increased risks of cardiovascular disease.
@en
P2093
P1476
Schizophrenia and increased risks of cardiovascular disease.
@en
P2093
Alissa R Hennekens
Charles H Hennekens
Daniel E Casey
Danielle Hollar
P304
P356
10.1016/J.AHJ.2005.02.007
P407
P577
2005-12-01T00:00:00Z